<DOC>
	<DOCNO>NCT02169414</DOCNO>
	<brief_summary>The purpose study determine effect BIA 9 1067 ( 5 mg , 15 mg 50 mg ) steady-state condition levodopa pharmacokinetics single dose immediate-release levodopa/carbidopa 100/25 mg single dose immediate-release levodopa/benserazide 100/25 mg .</brief_summary>
	<brief_title>Effect Three Multiple-dose Regimens BIA 9 1067 Steady-state Levodopa Pharmacokinetics</brief_title>
	<detailed_description>A single-centre , randomize , double-blind , gender-balanced , placebo-controlled study 4 group 18 healthy subject . This study consist once-daily administration BIA 9 1067 ( 5 mg , 15 mg 50 mg ) placebo 18 day . Twelve ( 12 ) hour BIA 9 1067 dose , single-dose levodopa/carbidopa 100/25 mg administer Day 11 single-dose levodopa/benserazide 100/25 mg administer Day 18 .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>able participate willing give write informed consent ; male female subject ; age 18 45 year , inclusive ; body mass index ( BMI ) 18 30 kg/m2 ; healthy determine Investigator basis medical history , physical examination , clinical laboratory test result , vital sign , complete neurological examination 12lead electrocardiogram ( ECG ) ; negative test hepatitis B surface ( HBs ) antigen , antihepatitis C virus ( HCV ) , human immunodeficiency virus1 ( HIV1 ) HIV2 antibodies screen ; negative screen drug abuse alcohol screen admission treatment period ; nonsmoker exsmokers least 3 month ; sexually active , agree use medically acceptable form contraception throughout study ; female childbearing potential , negative human chorionic gonadotropin ( HCG ) beta serum pregnancy test screen admission treatment period . conform inclusion criterion , case volunteer clinically relevant surgical history , clinically relevant family history ; history relevant atopy ; significant infection know inflammatory process screen admission treatment period ; acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhea , heartburn ) time screen admission treatment period ; vegetarian , vegan medical dietary restriction ; could communicate reliably Investigator ; unlikely cooperate requirement study ; history hypersensitivity BIA 9 1067 , tolcapone , entacapone , levodopa , carbidopa , benserazide relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug ; significant cardiovascular ( e.g . hypertension ) , hepatic , renal , respiratory ( e.g . childhood asthma ) , gastrointestinal , endocrine ( e.g . diabetes , dyslipidemia ) , immunologic , dermatological , haematological , neurologic , psychiatric disease ; clinically significant illness previous 28 day day 1 study ; history drug abuse within 1 year study day 1 ; history alcoholism within 1 year day 1 . Consumption 50 g ethanol per day ( 12.5 cL glass 10째 [ 10 % ] wine = 12 g ; 4 cL aperitif , 42째 [ 42 % ] whiskey = 17 g ; 25 cL glass 3째 [ 3 % ] beer = 7.5 g ; 25 cL glass 6째 [ 6 % ] beer = 15 g ) ; poor motivation , intellectual problem likely limit validity consent participate study limit ability comply protocol requirement inability cooperate adequately , inability understand observe instruction physician ; donation blood ( i.e. , 450 mL ) within 60 day study day 1 ; positive urine screen ethyl alcohol drug abuse upon admission treatment period ; history tuberculosis and/or prophylaxis tuberculosis ; positive result HIV , hepatitis B surface antigen ( HBsAg ) antiHCV test ; participation previous clinical study BIA 9 1067 ; female , pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Parkinson 's disease ( PD )</keyword>
	<keyword>BIA 9-1067</keyword>
	<keyword>Opicapone</keyword>
</DOC>